Is AXT (AXTI) Using Its New Board Seat to Reframe Its China Governance Story?

• AXT, Inc. recently expanded its board from five to six directors and appointed Jia-Bin Duh as an independent Class III director, effective July 16, 2026, with committee roles across audit, compensation, and nominating and corporate governance.
• Duh’s three decades of leadership in Greater China’s technology and consumer sectors, including senior roles at Microsoft China and Cisco Systems China, add substantial regional and governance expertise that could influence AXT’s international expansion and oversight of its China-based operations.
• Next, we’ll examine how bringing Jia-Bin Duh onto the board may reshape AXT’s investment narrative around governance and China-focused growth.

Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

AXT Investment Narrative Recap

To own AXT, you need to believe its compound semiconductor substrates can turn rising demand in data center and AI applications into a path back to profitability, despite export and margin headwinds. The short term catalyst remains execution on export permits and utilization, while the biggest risk stays concentrated China exposure and thin margins; adding Jia-Bin Duh looks additive on governance and China expertise, but does not by itself change those near term stakes.

Among recent developments, AXT’s upcoming Q2 2026 earnings on July 30 are especially relevant, as they will show whether operational trends are improving while the board is being refreshed. Analysts had already trimmed earnings expectations before Duh’s appointment, so investors may watch how a more experienced and independent board, now including Duh and Tracy Liu, supports tighter oversight of costs, export compliance, and China based operations.

Yet even with the board upgrade, investors should be aware that export permit uncertainty for key substrates could still...

Read the full narrative on AXT (it's free!)

AXT's narrative projects $374.9 million revenue and $141.0 million earnings by 2029. This requires 57.5% yearly revenue growth and a $155.3 million earnings increase from -$14.3 million today.

Uncover how AXT's forecasts yield a $96.50 fair value, a 82% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts are far more cautious, even before this board change, assuming revenue must reach about US$380.6 million and earnings US$189.5 million by 2029 for their case to work. If you are focused on how Duh’s China experience might help with regulatory friction, they instead worry that persistent export and customer concentration risks could keep pressure on AXT, so it is worth weighing how such expectations might shift after this news.

Explore 5 other fair value estimates on AXT - why the stock might be worth just $73.00!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AXT research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free AXT research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AXT's overall financial health at a glance.

Searching For A Fresh Perspective?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com